Across five retrospective comparative studies covering 27,341 patients, robotic-assisted revisional or conversional Roux-en-Y gastric bypass was linked to lower overall morbidity (OR 0.65, 95% CI 0.43-1.00) and fewer interventions for bleeding (OR 0.55, 95% CI 0.34-0.88) than laparoscopy. Reoperation, leak, hemorrhage, mortality, length of stay and operative time did not differ significantly. Both positive findings disappeared in leave-one-out analyses, and GRADE certainty was very low for every outcome.
For anyone weighing a revision after weight regain or sleeve complications, the practical message is that surgeon experience and center volume likely matter more than the platform. A confidence interval whose upper bound touches 1.00, a p-value of 0.049, and sensitivity to a single study's inclusion make this a hypothesis-generating signal, not evidence of superiority. The pooled sample is also dominated by large registry-style datasets, which carry heavy selection bias: surgeons choose robotic cases, often at high-volume centers with better perioperative systems, so the benefit may reflect who operates and where rather than the robot. Reassuringly, operative time was comparable and no safety penalty emerged, so robotic access does not appear harmful. Long-term outcomes patients care about, such as sustained weight loss, remission of type 2 diabetes, and reintervention rates, are absent here. Editorially, this is confirmatory and incremental. Randomized trials are unlikely, so prospective registries with standardized complication reporting are the realistic next step. Patients should ask their surgeon about personal revisional volume and complication rates rather than the instrument used.